Truncated Linker Design for Antibody-Drug Conjugate Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges in linker design, particularly in achieving optimal stability, specific cleavability in tumor cells, and maintaining good hydrophilicity and antibody affinity.
Innovation Solution
A PAB-free linker is designed to directly connect the primary amine structure of eribulin with an amino acid or short peptide, forming an amide bond, and a truncated linker concept is used to improve hydrophilicity and antibody-target protein affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a PAB group is added to the linker to provide enzyme cleavage space, then the ADC can self-cleave in the cell to release eribulin, but the hydrophilicity and antibody affinity are compromised
Solution Approach 1:
The patent removes the PAB group from the traditional PEG2-val-cit-PAB linker structure, retaining only the essential val-cit peptide sequence for enzyme cleavage. This extraction eliminates the hydrophobic PAB moiety while preserving the cleavable function, thereby improving hydrophilicity and antibody affinity without sacrificing the self-cleavage capability in tumor cells.
Solution Approach 2:
The patent modifies the linker composition by changing the chemical parameters - specifically removing the PAB group and adjusting the PEG chain length. This parameter change optimizes the balance between cleavability and hydrophilicity, allowing the ADC to maintain both self-cleavage function and improved solubility/affinity characteristics.
2Ease of manufacture
If a long PEG chain is used in the linker, then the hydrophilicity is improved, but the antibody affinity and molecular compactness deteriorate
Solution Approach 1:
The patent optimizes the PEG chain length parameter, using a shorter PEG2 unit instead of longer PEG chains. This parameter optimization provides sufficient hydrophilicity for the ADC molecule while avoiding excessive chain length that would compromise antibody affinity and molecular compactness, achieving a balanced design.
Solution Approach 2:
The patent applies local quality by concentrating the hydrophilic function in a specific, optimized PEG2 segment rather than using extended PEG chains throughout the linker. This localized approach provides necessary hydrophilicity at the linker region without allowing the long chain to interfere with the antibody's binding site or overall molecular structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new ADC design significantly enhances the hydrophilicity of the ADC molecule, improves the affinity between the antibody and the target protein, and increases anti-tumor efficacy.
Implementation Method 1
the maleimide group to connect to the amino acid or short peptide (e.g., Vc or Va structure) to form an amide bond
Data Source
AI summary
An antibody-drug conjugate having improved affinity, and a preparation method therefor and an application thereof. Specifically, provided are an antibody drug conjugate as shown in formula (II), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a solvate thereof. The antibody drug conjugate no only obviously improves the affinity of an antibody and a target protein, but also improves the hydrophilicity of an ADC molecule, and further improves the efficacy of tumor inhibition.